U.S. HIV Incidence and Transmission Goals, 2020 and 2025
Introduction The recently updated U.S. National HIV/AIDS Strategy sets key HIV prevention and care targets for 2020, but the trajectory of the epidemic remains unclear. Authors modeled HIV incidence, prevalence, and mortality for the U.S. over 10 years to determine whether an ambitious trajectory to...
Gespeichert in:
Veröffentlicht in: | American journal of preventive medicine 2017-09, Vol.53 (3), p.275-281 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 281 |
---|---|
container_issue | 3 |
container_start_page | 275 |
container_title | American journal of preventive medicine |
container_volume | 53 |
creator | Bonacci, Robert A., MD, MPH Holtgrave, David R., PhD |
description | Introduction The recently updated U.S. National HIV/AIDS Strategy sets key HIV prevention and care targets for 2020, but the trajectory of the epidemic remains unclear. Authors modeled HIV incidence, prevalence, and mortality for the U.S. over 10 years to determine whether an ambitious trajectory toward “ending AIDS” by 2025 would be achievable. Methods Authors utilized recently published 2010–2013 Centers for Disease Control and Prevention surveillance data to model HIV incidence, prevalence, and mortality. Authors applied a 90/90/90 framework (90% awareness of serostatus, 90% of diagnosed individuals in care, and 90% of individuals on antiretroviral therapy virally suppressed) by 2020 and 95/95/95 by 2025 to assess the feasibility of meeting epidemiologic targets. Analyses were conducted in 2016. Results With a goal of reducing infections to 21,000 new HIV infections in 2020, authors project a transmission rate of 1.74, 12,571 deaths, and a total of 1,205,515 people living with HIV. By 2025, with a target of 12,000 new HIV infections (a 69% decrease in HIV incidence), authors project a transmission rate of 0.98, 12,522 deaths, and a total of 1,220,615 people living with HIV. With a 90/90/90 framework by 2020 and a 95/95/95 framework by 2025, these epidemiologic targets would be feasible. Conclusions Key programmatic milestones provide an ambitious, but important, pathway to reduce U.S. HIV incidence below 12,000 new infections by 2025. HIV incidence would decrease below mortality in 2025, marking a transition toward ending the HIV/AIDS epidemic. Such goals will require a sustained and intensified national commitment over the next decade. |
doi_str_mv | 10.1016/j.amepre.2017.03.012 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1900832872</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0749379717302027</els_id><sourcerecordid>1900832872</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-34a9291e02a6d87ecc7bfa6db087d81df7dd88726829f014cbcba613998ed0e83</originalsourceid><addsrcrecordid>eNqFkUFv1DAQhS0EokvhHyAUiQsHEsbjbMa-IKEK2pUqcWjL1XLsieQlmyz2LlL_PQ5beuiFk0f2e2_G3wjxVkIjQXafto3b8T5xgyCpAdWAxGdiJTWpGjug52IF1JpakaEz8SrnLQCQlualOEO9RkRFK6Hvmpumutr8qDaTj4Enz5WbQnWb3JR3Mec4T9Xl7Mb8sUJA-PtYivVr8WIot_zm4TwXd9--3l5c1dffLzcXX65r37brQ61aZ9BIBnRd0MTeUz-UsgdNQcswUAhaE3YazQCy9b3vXSeVMZoDsFbn4sMpd5_mX0fOB1um8jyObuL5mK00AFphiSjS90-k2_mYpjKdLYxahWT0uqjak8qnOefEg92nuHPp3kqwC1m7tSeyi4ssKFvIFtu7h_Bjv-PwaPqHsgg-nwRcaPyOnGz2ceEZYmJ_sGGO_-vwNMCPcYrejT_5nvPjX6TNaMHeLNtdlitJlcUgqT_hZJuC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2014327985</pqid></control><display><type>article</type><title>U.S. HIV Incidence and Transmission Goals, 2020 and 2025</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Bonacci, Robert A., MD, MPH ; Holtgrave, David R., PhD</creator><creatorcontrib>Bonacci, Robert A., MD, MPH ; Holtgrave, David R., PhD</creatorcontrib><description>Introduction The recently updated U.S. National HIV/AIDS Strategy sets key HIV prevention and care targets for 2020, but the trajectory of the epidemic remains unclear. Authors modeled HIV incidence, prevalence, and mortality for the U.S. over 10 years to determine whether an ambitious trajectory toward “ending AIDS” by 2025 would be achievable. Methods Authors utilized recently published 2010–2013 Centers for Disease Control and Prevention surveillance data to model HIV incidence, prevalence, and mortality. Authors applied a 90/90/90 framework (90% awareness of serostatus, 90% of diagnosed individuals in care, and 90% of individuals on antiretroviral therapy virally suppressed) by 2020 and 95/95/95 by 2025 to assess the feasibility of meeting epidemiologic targets. Analyses were conducted in 2016. Results With a goal of reducing infections to 21,000 new HIV infections in 2020, authors project a transmission rate of 1.74, 12,571 deaths, and a total of 1,205,515 people living with HIV. By 2025, with a target of 12,000 new HIV infections (a 69% decrease in HIV incidence), authors project a transmission rate of 0.98, 12,522 deaths, and a total of 1,220,615 people living with HIV. With a 90/90/90 framework by 2020 and a 95/95/95 framework by 2025, these epidemiologic targets would be feasible. Conclusions Key programmatic milestones provide an ambitious, but important, pathway to reduce U.S. HIV incidence below 12,000 new infections by 2025. HIV incidence would decrease below mortality in 2025, marking a transition toward ending the HIV/AIDS epidemic. Such goals will require a sustained and intensified national commitment over the next decade.</description><identifier>ISSN: 0749-3797</identifier><identifier>EISSN: 1873-2607</identifier><identifier>DOI: 10.1016/j.amepre.2017.03.012</identifier><identifier>PMID: 28522237</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Acquired immune deficiency syndrome ; Acquired Immunodeficiency Syndrome - drug therapy ; Acquired Immunodeficiency Syndrome - epidemiology ; Acquired Immunodeficiency Syndrome - prevention & control ; AIDS ; AIDS Serodiagnosis ; Ambition ; Anti-HIV Agents - therapeutic use ; Antiretroviral drugs ; Antiretroviral therapy ; Centers for Disease Control and Prevention (U.S.) - statistics & numerical data ; Disease control ; Disease prevention ; Disease Transmission, Infectious - prevention & control ; Disease Transmission, Infectious - statistics & numerical data ; Epidemics ; Feasibility ; Goals ; HIV ; HIV Seropositivity - epidemiology ; Human immunodeficiency virus ; Humans ; Incidence ; Internal Medicine ; Mortality ; Mortality - trends ; National plans ; Prevalence ; Preventive medicine ; Surveillance ; United States - epidemiology</subject><ispartof>American journal of preventive medicine, 2017-09, Vol.53 (3), p.275-281</ispartof><rights>American Journal of Preventive Medicine</rights><rights>2017 American Journal of Preventive Medicine</rights><rights>Copyright © 2017 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Sep 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-34a9291e02a6d87ecc7bfa6db087d81df7dd88726829f014cbcba613998ed0e83</citedby><cites>FETCH-LOGICAL-c445t-34a9291e02a6d87ecc7bfa6db087d81df7dd88726829f014cbcba613998ed0e83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.amepre.2017.03.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,30999,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28522237$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bonacci, Robert A., MD, MPH</creatorcontrib><creatorcontrib>Holtgrave, David R., PhD</creatorcontrib><title>U.S. HIV Incidence and Transmission Goals, 2020 and 2025</title><title>American journal of preventive medicine</title><addtitle>Am J Prev Med</addtitle><description>Introduction The recently updated U.S. National HIV/AIDS Strategy sets key HIV prevention and care targets for 2020, but the trajectory of the epidemic remains unclear. Authors modeled HIV incidence, prevalence, and mortality for the U.S. over 10 years to determine whether an ambitious trajectory toward “ending AIDS” by 2025 would be achievable. Methods Authors utilized recently published 2010–2013 Centers for Disease Control and Prevention surveillance data to model HIV incidence, prevalence, and mortality. Authors applied a 90/90/90 framework (90% awareness of serostatus, 90% of diagnosed individuals in care, and 90% of individuals on antiretroviral therapy virally suppressed) by 2020 and 95/95/95 by 2025 to assess the feasibility of meeting epidemiologic targets. Analyses were conducted in 2016. Results With a goal of reducing infections to 21,000 new HIV infections in 2020, authors project a transmission rate of 1.74, 12,571 deaths, and a total of 1,205,515 people living with HIV. By 2025, with a target of 12,000 new HIV infections (a 69% decrease in HIV incidence), authors project a transmission rate of 0.98, 12,522 deaths, and a total of 1,220,615 people living with HIV. With a 90/90/90 framework by 2020 and a 95/95/95 framework by 2025, these epidemiologic targets would be feasible. Conclusions Key programmatic milestones provide an ambitious, but important, pathway to reduce U.S. HIV incidence below 12,000 new infections by 2025. HIV incidence would decrease below mortality in 2025, marking a transition toward ending the HIV/AIDS epidemic. Such goals will require a sustained and intensified national commitment over the next decade.</description><subject>Acquired immune deficiency syndrome</subject><subject>Acquired Immunodeficiency Syndrome - drug therapy</subject><subject>Acquired Immunodeficiency Syndrome - epidemiology</subject><subject>Acquired Immunodeficiency Syndrome - prevention & control</subject><subject>AIDS</subject><subject>AIDS Serodiagnosis</subject><subject>Ambition</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>Centers for Disease Control and Prevention (U.S.) - statistics & numerical data</subject><subject>Disease control</subject><subject>Disease prevention</subject><subject>Disease Transmission, Infectious - prevention & control</subject><subject>Disease Transmission, Infectious - statistics & numerical data</subject><subject>Epidemics</subject><subject>Feasibility</subject><subject>Goals</subject><subject>HIV</subject><subject>HIV Seropositivity - epidemiology</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Incidence</subject><subject>Internal Medicine</subject><subject>Mortality</subject><subject>Mortality - trends</subject><subject>National plans</subject><subject>Prevalence</subject><subject>Preventive medicine</subject><subject>Surveillance</subject><subject>United States - epidemiology</subject><issn>0749-3797</issn><issn>1873-2607</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqFkUFv1DAQhS0EokvhHyAUiQsHEsbjbMa-IKEK2pUqcWjL1XLsieQlmyz2LlL_PQ5beuiFk0f2e2_G3wjxVkIjQXafto3b8T5xgyCpAdWAxGdiJTWpGjug52IF1JpakaEz8SrnLQCQlualOEO9RkRFK6Hvmpumutr8qDaTj4Enz5WbQnWb3JR3Mec4T9Xl7Mb8sUJA-PtYivVr8WIot_zm4TwXd9--3l5c1dffLzcXX65r37brQ61aZ9BIBnRd0MTeUz-UsgdNQcswUAhaE3YazQCy9b3vXSeVMZoDsFbn4sMpd5_mX0fOB1um8jyObuL5mK00AFphiSjS90-k2_mYpjKdLYxahWT0uqjak8qnOefEg92nuHPp3kqwC1m7tSeyi4ssKFvIFtu7h_Bjv-PwaPqHsgg-nwRcaPyOnGz2ceEZYmJ_sGGO_-vwNMCPcYrejT_5nvPjX6TNaMHeLNtdlitJlcUgqT_hZJuC</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Bonacci, Robert A., MD, MPH</creator><creator>Holtgrave, David R., PhD</creator><general>Elsevier Inc</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7X8</scope></search><sort><creationdate>20170901</creationdate><title>U.S. HIV Incidence and Transmission Goals, 2020 and 2025</title><author>Bonacci, Robert A., MD, MPH ; Holtgrave, David R., PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-34a9291e02a6d87ecc7bfa6db087d81df7dd88726829f014cbcba613998ed0e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Acquired Immunodeficiency Syndrome - drug therapy</topic><topic>Acquired Immunodeficiency Syndrome - epidemiology</topic><topic>Acquired Immunodeficiency Syndrome - prevention & control</topic><topic>AIDS</topic><topic>AIDS Serodiagnosis</topic><topic>Ambition</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>Centers for Disease Control and Prevention (U.S.) - statistics & numerical data</topic><topic>Disease control</topic><topic>Disease prevention</topic><topic>Disease Transmission, Infectious - prevention & control</topic><topic>Disease Transmission, Infectious - statistics & numerical data</topic><topic>Epidemics</topic><topic>Feasibility</topic><topic>Goals</topic><topic>HIV</topic><topic>HIV Seropositivity - epidemiology</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Incidence</topic><topic>Internal Medicine</topic><topic>Mortality</topic><topic>Mortality - trends</topic><topic>National plans</topic><topic>Prevalence</topic><topic>Preventive medicine</topic><topic>Surveillance</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bonacci, Robert A., MD, MPH</creatorcontrib><creatorcontrib>Holtgrave, David R., PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of preventive medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bonacci, Robert A., MD, MPH</au><au>Holtgrave, David R., PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>U.S. HIV Incidence and Transmission Goals, 2020 and 2025</atitle><jtitle>American journal of preventive medicine</jtitle><addtitle>Am J Prev Med</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>53</volume><issue>3</issue><spage>275</spage><epage>281</epage><pages>275-281</pages><issn>0749-3797</issn><eissn>1873-2607</eissn><abstract>Introduction The recently updated U.S. National HIV/AIDS Strategy sets key HIV prevention and care targets for 2020, but the trajectory of the epidemic remains unclear. Authors modeled HIV incidence, prevalence, and mortality for the U.S. over 10 years to determine whether an ambitious trajectory toward “ending AIDS” by 2025 would be achievable. Methods Authors utilized recently published 2010–2013 Centers for Disease Control and Prevention surveillance data to model HIV incidence, prevalence, and mortality. Authors applied a 90/90/90 framework (90% awareness of serostatus, 90% of diagnosed individuals in care, and 90% of individuals on antiretroviral therapy virally suppressed) by 2020 and 95/95/95 by 2025 to assess the feasibility of meeting epidemiologic targets. Analyses were conducted in 2016. Results With a goal of reducing infections to 21,000 new HIV infections in 2020, authors project a transmission rate of 1.74, 12,571 deaths, and a total of 1,205,515 people living with HIV. By 2025, with a target of 12,000 new HIV infections (a 69% decrease in HIV incidence), authors project a transmission rate of 0.98, 12,522 deaths, and a total of 1,220,615 people living with HIV. With a 90/90/90 framework by 2020 and a 95/95/95 framework by 2025, these epidemiologic targets would be feasible. Conclusions Key programmatic milestones provide an ambitious, but important, pathway to reduce U.S. HIV incidence below 12,000 new infections by 2025. HIV incidence would decrease below mortality in 2025, marking a transition toward ending the HIV/AIDS epidemic. Such goals will require a sustained and intensified national commitment over the next decade.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>28522237</pmid><doi>10.1016/j.amepre.2017.03.012</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0749-3797 |
ispartof | American journal of preventive medicine, 2017-09, Vol.53 (3), p.275-281 |
issn | 0749-3797 1873-2607 |
language | eng |
recordid | cdi_proquest_miscellaneous_1900832872 |
source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Acquired immune deficiency syndrome Acquired Immunodeficiency Syndrome - drug therapy Acquired Immunodeficiency Syndrome - epidemiology Acquired Immunodeficiency Syndrome - prevention & control AIDS AIDS Serodiagnosis Ambition Anti-HIV Agents - therapeutic use Antiretroviral drugs Antiretroviral therapy Centers for Disease Control and Prevention (U.S.) - statistics & numerical data Disease control Disease prevention Disease Transmission, Infectious - prevention & control Disease Transmission, Infectious - statistics & numerical data Epidemics Feasibility Goals HIV HIV Seropositivity - epidemiology Human immunodeficiency virus Humans Incidence Internal Medicine Mortality Mortality - trends National plans Prevalence Preventive medicine Surveillance United States - epidemiology |
title | U.S. HIV Incidence and Transmission Goals, 2020 and 2025 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A15%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=U.S.%20HIV%20Incidence%20and%20Transmission%20Goals,%202020%20and%202025&rft.jtitle=American%20journal%20of%20preventive%20medicine&rft.au=Bonacci,%20Robert%20A.,%20MD,%20MPH&rft.date=2017-09-01&rft.volume=53&rft.issue=3&rft.spage=275&rft.epage=281&rft.pages=275-281&rft.issn=0749-3797&rft.eissn=1873-2607&rft_id=info:doi/10.1016/j.amepre.2017.03.012&rft_dat=%3Cproquest_cross%3E1900832872%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2014327985&rft_id=info:pmid/28522237&rft_els_id=1_s2_0_S0749379717302027&rfr_iscdi=true |